Keyphrases
Body Mass Index
16%
Comorbidity
16%
Exercise Program
16%
Health Impact
16%
Health-related Quality of Life
100%
Liraglutide 3.0 Mg
100%
Negative Impact
16%
Obesity
33%
Obesity Body Mass Index
16%
Once-daily
16%
Patients with Obesity
16%
Placebo
100%
Pre-diabetes (pre-DM)
16%
Short Form 36 (SF-36)
83%
Treatment Difference
16%
Weight Management
100%
Medicine and Dentistry
Body Mass Index
22%
Comorbidity
11%
Impaired Glucose Tolerance
11%
Liraglutide
100%
Obesity
11%
Patient with Obesity
11%
Placebo
100%
Quality of Life
100%
Short Form 36
55%
Weight Management
100%
Pharmacology, Toxicology and Pharmaceutical Science
Comorbidity
16%
Impaired Glucose Tolerance
16%
Liraglutide
100%
Obesity
16%
Placebo
100%
Immunology and Microbiology
Body Mass
100%
Comorbidity
50%